Sinclair Pharma partners with Invida in Asia Pacific and with Sunstar in USA

London, UK-based Sinclair Pharma (LSE: SPH) saw its shares leap 19.7% to 39.25 pence on Tuesday, after the company announced a long-term partnership for the commercialization of its market leading brands in Asia Pacific with Singapore-headquartered Invida Holdings. The stock rose further yesterday on a second deal announcement with Sunstar, giving the UK firm a market capitalization of about £90 million ($141.5 million).

Invida is the region’s leading specialty biopharmaceutical company with over 4,000 employees and a presence in all major markets, and has recently entered into drug commercialization deals with Ipsen of France and Swiss biotechnology firm Actelion (The Pharma Letters passim).

Under the collaboration agreement, Invida will be Sinclair’s exclusive partner in 11 markets within the Asia Pacific region for its dermatology and wound care brands in what is expected to be at least a 20 year partnership. In the first phase, Invida will register and launch a number of Sinclair’s market-leading dermatology brands in the following markets - Australia, China, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. Additional launches of new Sinclair products are then expected over the next 2-3 years.